Loading clinical trials...
Loading clinical trials...
Phase 1, Dose Escalation, Non-Randomized, Open Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells (AMSCs) for Recurrent Glioblastoma
Conditions
Interventions
Allogeneic Adipose-derived Mesenchymal Stem Cells
Biospecimen Collection
+3 more
Locations
1
United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Start Date
June 16, 2023
Primary Completion Date
July 24, 2027
Completion Date
July 24, 2027
Last Updated
April 2, 2026
NCT06860594
NCT06410248
NCT05432804
NCT02766699
NCT06017063
NCT05218408
Lead Sponsor
Mayo Clinic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions